Sacituzumab Govitecan for HR+/HER2- advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR-positive, HER2-negative that has spread or cannot be removed with surgery.
- Your cancer got worse while on or soon after a CDK4/6 inhibitor (a common targeted therapy).
- You have had no more than 1 type of chemotherapy or antibody-drug conjugate for advanced breast cancer.
- You are willing to have a tumor biopsy before treatment and again after 2 weeks and at the end of treatment.
- You have adequate kidney, liver, and bone marrow function and are generally healthy enough for daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
This study tests a new drug combo (sacituzumab govitecan plus hormone therapy) for people whose HR+/HER2- breast cancer has progressed after a CDK4/6 inhibitor. It aims to see if this treatment can work better than hormones alone, and it may be an option if you've not yet had chemo for advanced disease.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
Hear when a new Breast Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.